Kryxana 200mg Tablet 21s

Kryxana 200mg Tablet 21s is a targeted oral medicine used to treat advanced or metastatic breast cancer in adults. It belongs to a class of drugs known as CDK4/6 inhibitors and works by blocking specific proteins that allow cancer cells to grow and divide. Kryxana 200mg Tablet 21s is typically prescribed in combination with hormone therapy (such as an aromatase inhibitor or fulvestrant) for patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) breast cancer. Taken as part of a cycle-based treatment plan, it helps slow disease progression and supports long-term management of advanced cancer.

Kryxana 200mg Tablet 21s is a targeted cancer therapy that helps slow the growth of advanced breast cancer by interfering with the cell division cycle. It is specifically used for hormone receptor-positive (HR+), HER2-negative (HER2-) breast cancer that has spread to other parts of the body.

Ribociclib works by inhibiting cyclin-dependent kinases 4 and 6 (CDK4/6). These enzymes are often overactive in breast cancer cells, acting as "on-switches" that signal the cells to divide and multiply. By blocking these kinases, Kryxana 200mg Tablet 21s halts the cell cycle at a specific point, preventing the DNA replication necessary for cancer cells to replicate. This action helps reduce the tumour's growth rate and can even shrink existing tumours when used alongside hormonal therapies.

The medicine is usually taken once daily for 21 consecutive days, followed by a 7-day break to allow the body's healthy cells to recover. Because it specifically targets the cell cycle, it offers a more focused approach compared to traditional chemotherapy. Regular monitoring by a physician is essential during treatment to check for impacts on heart rhythm and blood counts, ensuring the therapy remains both safe and effective for the patient.

Advanced Breast Cancer:

Treatment of HR-positive, HER2-negative metastatic breast cancer.

Combination Therapy:

Used in conjunction with endocrine therapies like letrozole or fulvestrant.

Initial/Subsequent Therapy:

Suitable as a first-line treatment or for patients whose cancer progressed after previous hormone therapy.

Delays Disease Progression:

Clinically proven to significantly increase the time a patient lives without the cancer growing or spreading.

Targeted Action:

Specifically inhibits the proteins responsible for cancer cell division while sparing many healthy cell types.

Improved Quality of Life:

Helps manage symptoms by controlling tumour growth and may delay the need for aggressive chemotherapy.

Kryxana 200mg Tablet 21s can cause side effects as it impacts the cell division cycle. While many patients tolerate it well, monitoring is necessary to manage potential reactions.

Common Side Effects:

• Neutropenia: A decrease in white blood cells, which may increase the risk of infections.
• Fatigue: Feeling unusually tired or weak.
• Gastrointestinal Issues: Nausea, diarrhoea, vomiting or mouth sores (stomatitis).
• Anaemia: Reduced red blood cell count leading to tiredness or shortness of breath.
• Hair Thinning: Mild to moderate hair loss (alopecia).
• Skin Changes: Rash or dry skin.

Serious Side Effects (Seek urgent medical attention if you experience):

• Signs of Infection: Fever, chills, sore throat, or persistent cough (due to low white blood cell counts).
• Heart Rhythm Changes (QT Prolongation): Fainting, dizziness, or a racing/irregular heartbeat.
• Liver Problems: Yellowing of the eyes or skin (jaundice), dark urine, or pain in the upper right side of the stomach.
• Lung Inflammation: New or worsening cough, chest pain, or difficulty breathing (interstitial lung disease).
• Severe Skin Reactions: Peeling, blistering, or painful rashes that spread quickly.

• Dosage: The standard dose is 600 mg (three 200 mg tablets) once daily for 21 days, followed by 7 days off.
• Administration: Swallow tablets whole with water at the same time each day, with or without food.
• Avoidance: Do not crush, chew, or break the tablets. Avoid grapefruit products during treatment.
• Missed Dose: If you miss a dose or vomit, do not take an extra dose; take your next dose at the regular time.

• Monitor for Fever: Contact your doctor immediately if you develop a fever or signs of infection, as your white blood cell count may be low.
• Heart Checks: Attend all scheduled ECG appointments to monitor your heart's electrical activity.
• Consistency: Take the medicine at the same time every day to maintain a steady level in your bloodstream.

• Store Kryxana 200mg Tablet 21s in its original packaging at room temperature, ideally between 20°C and 25°C (68°F to 77°F).
• Keep the medicine away from excessive heat, moisture, and direct sunlight.
• Always keep the tablets out of the reach of children and pets.
• Do not use the medicine after the expiry date printed on the packaging.

• Grapefruit/Pomegranate: Inhibits the enzymes that break down the drug, leading to potentially toxic levels in the body.

• CYP3A4 Inhibitors: (e.g., Ketoconazole, Ritonavir) can increase drug concentration.
• QT-Prolonging Drugs: (e.g., certain anti-arrhythmics or antibiotics) increase the risk of heart rhythm issues.
• CYP3A4 Inducers: (e.g., Rifampin, St. John’s Wort) can make the medicine less effective.

• Heart Conditions: Patients with long QT syndrome or electrolyte imbalances (low potassium/magnesium) are at higher risk.
• Active Infections: Lowered white blood cell counts may make it harder to fight off current infections.

The standard starting dose of Kryxana 200mg Tablet 21s is 600 mg (three 200 mg tablets) taken orally once daily for 21 consecutive days, followed by 7 days off treatment (making a 28-day cycle). The tablets should be taken at approximately the same time each day, preferably in the morning, and can be taken with or without food. Your healthcare provider may reduce the dose to 400 mg or 200 mg if you experience certain side effects.

In the event of a suspected overdose, seek immediate emergency medical care or contact a poison control centre. Symptoms of overdose may include severe nausea, vomiting, or signs of acute toxicity like severe low blood cell counts (neutropenia). Because Ribociclib can affect heart rhythm, clinical monitoring, including an ECG (electrocardiogram), is essential to check for QT prolongation. Treatment is generally supportive based on the symptoms presented.

If you miss a dose or vomit after taking your dose, do not take an additional dose that day. Skip the missed dose and take your next dose at your regular scheduled time. Do not take two doses at once to make up for a missed one.